Equation Predicts Risk of End-Stage Renal Disease in Children

Share this content:
Equation Predicts Risk of End-Stage Renal Disease in Children
Equation Predicts Risk of End-Stage Renal Disease in Children

MONDAY, Dec. 18, 2017 (HealthDay News) -- The kidney failure risk equation (KFRE) is a simple tool that provides excellent discrimination of the risk of end-stage renal disease (ESRD) in children with chronic kidney disease (CKD), according to a study published online Dec. 18 in JAMA Pediatrics.

Erica Winnicki, M.D., from the University of California in San Francisco, and colleagues retrospectively analyzed data from 603 children with an estimated glomerular filtration rate of <60 mL/min/1.73 m² participating in the Chronic Kidney Disease in Children study (Jan. 1, 2005, through July 31, 2013). The predictive ability of the four- and eight-variable KFRE was tested by evaluating time to ESRD in children with CKD.

The researchers found that over a median observation time of 3.8 years, 144 participants (23.9 percent) developed ESRD within five years of enrollment. The predictive abilities of the four- and eight-variable KFRE scores were similar for discrimination of ESRD risk (C statistics of 0.90, 0.86, and 0.81 for the one-, two-, and five-year four-variable KFRE risk scores, respectively; 0.91, 0.87, and 0.82, respectively, for the eight-variable KFRE scores).

"Results suggest that the KFRE could be incorporated into the clinical care of children with CKD to aid in anticipatory guidance, timing of referral for transplant evaluation, and planning for dialysis access," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »